FOLH1 and prostate cancer: Janssen et al. compared Ga-68 PSMA PET/CT with Tc-99m diphosphono-1,2-propanodicarboxylic acid (Tc-99m DPD) bone scan including SPECT/CT in 54 prostate cancer patients and found both sensitivity and specificity of Ga-68 PSMA PET/CT as 100%, while they were 82.8% and 84% for Tc-99m DPD SPECT/CT [16].